Clinical Trial Update: NRX-1074 in Early Course Schizophrenia [Phase 2]

View source ↗

Summary

A Phase 2 trial of NRX-1074 for early course schizophrenia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• NRX-1074 (NRX-1074)

Snippet

Sponsor: NYU Langone Health | Conditions: Schizophrenia | Phase 2 | Status: WITHDRAWN